CardioVascular BioTherapeutics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile (Global Markets Direct)

CardioVascular BioTherapeutics, Inc. (Cardio) is a development-stage biopharmaceutical company focused on developing drugs to stimulate the growth of new blood vessels for the treatment of cardiovascular diseases. The active pharmaceutical ingredient (API) in the Company’s drug candidates is acidic human fibroblast growth factor-1, FGF-1141 (formerly called Cardio Vascu-Grow) and it facilitates the growth of new blood vessels in the heart tissues and organs with an impaired vascular system. This process is referred to as angiogenesis in the scientific community. The Company’s research and development is focused on developing new drug candidates, in which FGF-1141 is the API for the treatment of cardiovascular diseases, where the growth of new blood vessels can improve the outcome for patients. The Company conducts research to identify and evaluate medical indications that may benefit from its drug candidates.

CardioVascular BioTherapeutics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Cardiovascular Biotherapeutics, Inc. (CVBT) is a biopharmaceutical company. It is engaged in the development of protein drugs for the treatment of regenerative cardiovascular diseases. The company's development stage product facilitates the growth of new blood vessels in the heart, tissues and organs. Its primary product candidate FGF-1 (141), is designed to facilitate the growth of new blood vessels in the heart and other tissues and organs with an impaired vascular system and is currently undergoing Phase II clinical trials for treatment of coronary heart disease. The company is headquartered in Las Vegas, United States.

The CardioVascular BioTherapeutics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.

Scope

- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

- A quick "one-stop-shop" to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.